Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230866 · ClinicalTrials.gov registry record · Phase 3
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Proton Collaborative Group.
- Active
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 5
- Study locations
NCT01230866: Active Phase 3 study of Prostate Cancer, sponsored by Proton Collaborative Group.
NCT01230866 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Proton Collaborative Group. The registered enrollment target is 150 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01230866, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Proton Collaborative Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks) with a higher daily dose of radiation (5 treatments over 1-2 weeks) to see if the effects of the treatments are similar or better.
Primary Outcome
The events for FFF will be the first occurrence of clinical failure (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the Phoenix definition (PSA ≥ 2 ng/ml over the current nadir PSA),or the start of salvage therapy including androgen deprivation.
Conditions Studied
Interventions
- RADIATION Proton Radiation Hypofractionation
- RADIATION Proton Radiation Standard Fractionation
Study Locations (5)
Arizona
- Mayo Clinic Cancer Center - Phoenix
Illinois
- Northwestern Medicine Chicago Proton Center - Warrenville
Maryland
- Maryland Proton Treatment Center - Baltimore
Oklahoma
- Oklahoma Proton Center - Oklahoma City
Virginia
- Hampton University Proton Therapy Institute - Hampton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2010-11 |
| Phase | Phase 3 |
What the registry record for NCT01230866 still lists
NCT01230866 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Proton Radiation Hypofractionation is the first listed.
NCT01230866 lists 5 locations in 5 states (Arizona, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT01230866 about?
NCT01230866 is a clinical study titled "Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer". The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks) with a higher daily dose of radiation (5 treatments over 1-2 weeks) to see if the effects of the treatments are simi...
What is the current status of trial NCT01230866?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2010-11.
What conditions does trial NCT01230866 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01230866?
The interventions under investigation include: Proton Radiation Hypofractionation (RADIATION), Proton Radiation Standard Fractionation (RADIATION).
Who is sponsoring clinical trial NCT01230866?
This trial is sponsored by Proton Collaborative Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01230866 being conducted?
This trial has 5 study locations across Arizona, Illinois, Maryland, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01230866's enrollment target sits among peer trials
150 260th of 735 higher than 464 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02455479 · 150 participants · Phase 1
Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia